Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug

Health
By Gina Kolata and Pam Belluck from NYT Health https://ift.tt/Qyuisxc
via IFTTT Drugs (Pharmaceuticals), Alzheimer's Disease, Brain, Memory, Leqembi (Drug), Clinical Trials, your-feed-science, your-feed-healthcare The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda